New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
05:38 EDTHSP, MDCOThe Medicines Co. provides update on Angiomax patent litigation
On March 31, Judge Andrews in the U.S. District Court of Delaware issued his Trial Opinion in The Medicines Company v. Hospira, Inc. The case involves Hospira's (HSP) Abbreviated New Drug Applications, or ANDAs, seeking approval to commercially manufacture, use or sell a generic version of The Medicines Company's (MDCO) Angiomax bivalirudin drug product before the expiration of the patents covering this product. The Delaware Decision follows a September 23-25, 2013 bench trial. With respect to patent validity, the Court held that the two patents in the case, U.S. Patent Nos. 7,582,727 and 7,598,343 were valid on all grounds. Specifically, the Court found that Hospira had failed to prove that the patents were either anticipated and/or obvious. The Court further held that the patents satisfied the written description requirement, were enabled and were not indefinite. With respect to infringement, based on its July 2013 Markman Decision, the Court found that Hospira's ANDAs did not meet the "efficient mixing" claim limitation and thus did not infringe the asserted claims of the '727 and '343 patents. The Court found that the other claim limitations in dispute were present in Hospira's ANDA products. The Court has not yet entered a final judgment. Any appeal to the Court of Appeals for the Federal Circuit would need to be filed within 30 days of such entry. The '727 and '343 patents expire in 2028.
News For MDCO;HSP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
07:07 EDTMDCOThe Medicines Co. settles with Sun, says can market generic Angiomax
The Medicines Company announced that it has settled its litigation with Sun Pharmaceutical Industries and certain of its subsidiaries relating to MDCO’s U.S. Patent No. 7,582,727 and U.S. Patent No. 7,598,343 covering Angiomax, bivalirudin. As a result of the settlement, MDCO will permit a Sun Pharma subsidiary to market a generic bivalirudin product in the United States on June 30, 2019, or earlier in certain limited circumstances. This settlement validates MDCO’s patents while allowing a Sun Pharma subsidiary to enter the market with its generic product. The agreement will be submitted to the applicable governmental agencies for review.
March 30, 2015
11:32 EDTHSPHospira announces availability of INFLECTRA in Canada
Subscribe for More Information
07:05 EDTMDCOThe Medicines Co. receives EC approval for three hospital acute care products
Subscribe for More Information
March 27, 2015
09:05 EDTHSPHospira presents two studies that evaluate proposed biosimilar, Epoetin Hospira
Subscribe for More Information
08:44 EDTMDCOThe Medicines Co. has a conference call hosted by JPMorgan
Subscribe for More Information
06:08 EDTMDCOThe Medicines Co. assumed with a Neutral at Citigroup
Target $30.
March 25, 2015
07:12 EDTMDCOAmerican Academy of Orthopedic Surgeons to hold annual meeting
Subscribe for More Information
March 23, 2015
09:03 EDTHSPPfenex announces early HSR clearance for collaboration with Hospira
Subscribe for More Information
March 20, 2015
10:00 EDTMDCOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
March 19, 2015
16:06 EDTMDCOThe Medicines Co. initiated with a Neutral at Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use